Researchers have taken a big step forward in the goal to "personalize" medicine by developing a tumor gene screen that can predict which women with breast cancer will respond to a common chemotherapy treatment before surgery.
Based on results of a Phase I trial that paired Imatinib mesylate (Gleevec (tm)) with chemotherapy to treat advanced prostate cancer, a larger Phase II/III clinical trial has just been opened at The University of Texas M. D. Anderson Cancer Center.
Examination of several multi-national cancer registries suggests that use of donor stem cells to treat metastatic breast cancer appears to delay progression of the disease in some patients.
Interim results of the first clinical trial to combine two experimental targeted therapies together to treat advanced non-small cell lung cancer found the regimen to be both safe and more beneficial than expected.
An anti-cancer pill just approved by the Food and Drug Administration as the first in a novel class of agents may offer some maintenance benefits in advanced non-small cell lung cancer, say investigators who conducted a sub-analysis of several large international clinical trials.
Less is perhaps more when it comes to using Imatinib mesylate (Gleevec (tm)) to treat advanced gastrointestinal stromal tumors (GIST), says a researcher from The University of Texas M. D. Anderson Cancer Center who presented results of a large multi-center trial testing different doses of the pill.
Adding docetaxel to the most commonly used combination chemotherapy improved tumor regression rate, delayed tumor growth and prolonged survival for patients with advanced stomach cancer, according to interim results of a Phase III international clinical trial.
Breast cancer in men is usually detected when the tumors are bigger, have spread and may be more aggressive, compared to diagnosis of the disease in women, concludes the largest study ever conducted of male breast cancer.
If all the blood vessels in the body were lined up end-to-end, they would form a line that could circle the earth twice. Yet the body produces still more blood vessels on demand, such as to heal wounds or grow embryos.
In a unique venture that partners academic medicine with the private sector, The University of Texas M. D. Anderson Cancer Center and its collaborators today (May 7) are breaking ground on a proton therapy center that will offer the most advanced innovation in radiation therapy to patients when it opens in 2006.
A research team led by The University of Texas M. D. Anderson Cancer Center has tested a novel "viral smart bomb" therapy that can completely eradicate brain tumors in mice, while leaving normal brain tissue alone.
Pediatricians need to give their patients more information about skin cancer prevention and sun protection, according to a recent study from The University of Texas M. D. Anderson Cancer Center.
An experimental agent that targets a cancer cell's protein shredding machinery (the proteasome) should be given either before or with taxane-based chemotherapy drugs, but not after, say researchers who conducted laboratory tests using prostate cancer cells.
If patients with breast cancer have tumor cells circulating in the blood, they may have a more dangerous form of the disease, according to a study by researchers at The University of Texas M. D. Anderson Cancer Center.
Researchers have, for the first time, identified the molecular pathway by which a commonly prescribed arthritis medication inhibits the growth of cancer.
Individuals who are especially susceptible to genetic damage to their cells and who don't eat enough dietary folate are almost three times as likely to develop bladder cancer as are those who eat plenty of fruit and vegetables and who have efficient capacity to repair DNA damage, say researchers.
Women with a common thyroid gland disorder appear to have a reduced chance of developing invasive breast cancer, say researchers at The University of Texas M. D. Anderson Cancer Center.
Researchers report that in laboratory animals, the combination of radiation and the anti-angiogenic drug, endostatin, appears to work synergistically together to stop development of new blood vessels that seek to grow and nourish damaged tumors.
Based on a large study of prostate cancer patients, researchers are finding that maintaining a normal body mass index, frequent physical activity and screening before diagnosis appear to be important in stopping prostate cancer from progressing.
Interim results of a large lung cancer case-control study suggest there is a genetic basis for development of lung cancer and other smoking related cancers, say researchers from The University of Texas M. D. Anderson Cancer Center.
Statin drugs used to lower cholesterol may also help prevent development of breast cancer, say researchers who studied the drugs in laboratory cell cultures.
Measuring a woman's leptin levels may offer an additional indicator of her risk of developing breast cancer, say researchers at The University of Texas M. D. Anderson Cancer Center.
For the first time, researchers are characterizing the molecular processes that turn brain cancer deadly, and their work may result in a diagnostic test that can predict patient survival.
Despite the fact that the death rate from prostate cancer is much higher in African-American men than in Caucasian men, little is known if prostate cancer biology could be different among the two racial groups.
Empowering women to take charge of their physical health as well as offering them the latest news in female-specific cancers, The University of Texas M. D. Anderson Cancer Center is hosting the Healthy Woman's Symposium and Luncheon 2003.
People who have a lower DNA repair capacity are at increased risk for melanoma skin cancer, according to a new study by scientists at The University of Texas M. D. Anderson Cancer Center. The study demonstrates for the first time a direct link between reduced capacity to repair damage to DNA genetic material and development of melanoma.
Use of a Vitamin A derivative in former smokers restored production of a crucial protein believed to protect against lung cancer development, researchers at The University of Texas M. D. Anderson Cancer Center have found.
Dr. Margaret Kripke of The University of Texas M. D. Anderson Cancer Center has been honored by two professional societies for her research in skin cancer.
Oncologists who learn how to communicate bad news and better handle patients' emotional reactions may improve their patients' quality of life, according to physicians at The University of Texas M. D. Anderson Cancer Center.
Studies of a drug for adults with a fatal form of brain cancer reportedly prolongs life with few side effects, say researchers at The University of Texas M. D. Anderson Cancer Center.
A new outpatient Center for Sympton Control andPalliative Care has opened at The University of Texas M. D. Anderson Cancer Center under the direction of Dr. Eduardo Bruera, newly appointed chairman of the Department of Symptom Control and Palliative Care.
Hundreds of cancer survivors, their families, friends and health care professionals from Texas and the nation will gather Sept. 24-25 for a conference that has become an annual celebration of survivorship.
Three physicians at the University of Texas M. D. Anderson Cancer Center are major architects of new prostate cancer detection and treatment guidelines released today by the National Comprehensive Cancer Network and the American Cancer Society.
The program, Prostate Cancer: A Journey of Hope, airs in some cities Friday, June 11, and stresses the importance of early detection for the disease, as well as the recommendation that men age 50 and older obtain an annual Prostate Specific Antigen (PSA) blood test and a digital rectal exam.
Findings of the Phase I medical study may have a huge impact on future treatments for the disease, especially for men with localized advanced prostate cancer, say Researchers at the University of Texas M. D. Anderson Cancer Centerr.
Smokers successfully treated for head and neck squamous cell cancer have greater chances of getting another cancer or having the cancer recur if they do not quit smoking, according to study at the University of Texas M. D. Anderson Cancer Center.
1- effectiveness of first oral chemotherapy for colon cancer; 2- new agent's promise against most serious brain tumors; 3- Taxotere increases survival rate for patients with non-small cell lung cancer.
Cancer patients wanting cutting-edge therapy or whose disease no longer responds to traditional treatment may find new hope on the "information super highway." The University of Texas M. D. Anderson Cancer Center has posted its clinical trials available for cancer patients on a World Wide Web site.
Postmenopausal women with advanced breast cancer treated with a new aromatase inhibitor live longer than patients treated with a commonly-used progestin, according to a report given today at the American Society of Clinical Oncology (ASCO).
Researchers at The University of Texas M. D. Anderson Cancer Center have found another anti-tumor drug that may prove useful in fighting lung cancer associated with smoking. The clinical trial at the Houston cancer center indicates the drug, topotecan, shows promise as a new treatment option for patients suffering from advanced non-small cell lung cancer.
An international study has found a new agent that may prove useful for treating patients with an aggressive brain tumor known as anaplastic astrocytoma.
EMBARGOED FOR RELEASE UNTIL 5 p.m., EST, THURSDAY, MARCH 27 HOUSTON -- Researchers at The University of Texas M. D. Anderson Cancer Center, in collaboration with Myriad Genetics, Inc. of Salt Lake City, have discovered a gene involved in the progression of a fatal form of brain cancer and a number of other cancers.
Researchers at The University of Texas M. D. Anderson Cancer Center have shined a bold new light on the future treatment of childhood leukemia. Results of a study published in the Jan. 30 issue of the New England Journal of Medicine not only refute a 30-year-old dogma universally held by the medical community, but also open new doors to a better understanding of acute lymphoblastic leukemia (ALL), the most common form of childhood cancer. Using two sensitive assays, M. D. Anderson researchers found that up to thousands of leukemia cells may remain in a patient long after successful treatment.